Arpad Illes

138 Böszörményi St
Debrecen, HB 4032, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 167 publications

Role of Autologous Haematopoietic Transplantation in Leukaemias: When to Consider It in 2026.

Role of Autologous Haematopoietic Transplantation in Leukaemias: When to Consider It in 2026.

Journal: Hematology reports

Published: June 09, 2026

Circulating CD117+/CD34+/CD45dim Myeloblasts as Biomarkers of Disease Activity in Primary Myelofibrosis-A Pilot Study.

Circulating CD117+/CD34+/CD45dim Myeloblasts as Biomarkers of Disease Activity in Primary Myelofibrosis-A Pilot Study.

Journal: EJHaem

Published: April 21, 2026

Pre-Engraftment Syndrome After Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: An Association with Prior PD-1 Inhibitor Exposure.

Pre-Engraftment Syndrome After Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: An Association with Prior PD-1 Inhibitor Exposure.

Journal: Medicina (Kaunas, Lithuania)

Published: February 16, 2026

Hodgkin Variant Richter's Transformation in the Absence of Classical Risk Factors: A Rare Case With Spinal Manifestation.

Hodgkin Variant Richter's Transformation in the Absence of Classical Risk Factors: A Rare Case With Spinal Manifestation.

Journal: Cureus

Published: February 13, 2026

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Journal: Blood cancer journal

Published: January 28, 2026

Bispecific Antibodies in B-Cell Lymphomas: Mechanisms, Efficacy, Toxicity, and Management.

Bispecific Antibodies in B-Cell Lymphomas: Mechanisms, Efficacy, Toxicity, and Management.

Journal: Medicina (Kaunas, Lithuania)

Published: January 06, 2026

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Journal: Lancet (London, England)

Published: October 24, 2025

Adipokines as Prognostic Biomarkers in Multiple Myeloma: A Case-Control Study.

Adipokines as Prognostic Biomarkers in Multiple Myeloma: A Case-Control Study.

Journal: Medicina (Kaunas, Lithuania)

Published: October 19, 2025

Antiangiogenic Treatment of Patients with Hereditary Hemorrhagic Telangiectasia: Experience of a Hungarian Center.

Antiangiogenic Treatment of Patients with Hereditary Hemorrhagic Telangiectasia: Experience of a Hungarian Center.

Journal: Journal of clinical medicine

Published: September 27, 2025

Hodgkin Lymphoma Associated with Common Variable Immunodeficiency: The Role of Early Diagnosis and Multidisciplinary Management.

Hodgkin Lymphoma Associated with Common Variable Immunodeficiency: The Role of Early Diagnosis and Multidisciplinary Management.

Journal: Hematology reports

Published: September 21, 2025

Sequencing Cellular Therapies in the Management of Follicular Lymphoma.

Sequencing Cellular Therapies in the Management of Follicular Lymphoma.

Journal: Cells

Published: September 08, 2025

Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.

Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.

Journal: Leukemia

Published: June 10, 2025

Showing 1-12 of 167

Last Updated: 09/26/2026